UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

Nicolette Natale, D.O., whose areas of expertise include the treatment of substance abuse disorders. Courtesy Nicolette Natale, D.O. According to ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

DAVENPORT, Iowa (KWQC) - The Food and Drug Administration recently approved Journavx to treat short-term pain. It’s a new class of non-opioid pain medication for treating adults and the first ...

Look for Journavx to become a massive blockbuster drug for Vertex. It won U.S. Food and Drug Administration (FDA) approval earlier this year for treating acute pain. The big plus for Journavx is that ...

The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company ...

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

Lastly, recent innovations in pain management, such as the FDA-approved Journavx™ (suzetrigine), will be discussed, offering a glimpse into the future of non-opioid therapies. By connecting ...

Journavx (suzetrigine), Vertex’s non-opioid NaV1.8 pain signal inhibitor, for the treatment of moderate-to-severe acute pain, was approved by the FDA in January 2025. At the fourth-quarter ...

“The FDA approval of suzetrigine (Journavx) opens the door to a new class of oral systemic medications for patients who suffer from acute pain, including pain after surgery,” says Dr. Edward ...